Organogenesis Holdings Inc. (NASDAQ:ORGO) Insider Lori Freedman Purchases 9,022 Shares

Organogenesis Holdings Inc. (NASDAQ:ORGO) insider Lori Freedman purchased 9,022 shares of the firm’s stock in a transaction on Friday, June 6th. The stock was bought at an average cost of $2.99 per share, with a total value of $26,975.78. Following the acquisition, the insider now owns 846,459 shares of the company’s stock, valued at approximately $2,530,912.41. The trade was a 1.08% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Lori Freedman also recently made the following trade(s):

• On Thursday, June 5th, Lori Freedman purchased 142,379 shares of Organogenesis stock. The stock was bought at an average cost of $2.91 per share, with a total value of $414,322.89.
• On Wednesday, June 4th, Lori Freedman purchased 100,863 shares of Organogenesis stock. The stock was bought at an average cost of $2.82 per share, with a total value of $284,433.66.

Organogenesis Trading Up 5.2%

Shares of Organogenesis stock opened at $3.03 on Friday. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.09 and a quick ratio of 2.74. The firm has a fifty day moving average price of $3.82 and a 200 day moving average price of $3.85. Organogenesis Holdings Inc. has a 1 year low of $2.28 and a 1 year high of $6.71. The stock has a market cap of $384.37 million, a PE ratio of -50.50 and a beta of 1.85.

Organogenesis (NASDAQ:ORGO) last issued its earnings results on Thursday, May 8th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.17). Organogenesis had a negative return on equity of 2.69% and a negative net margin of 1.62%. The business had revenue of $86.69 million for the quarter, compared to analysts’ expectations of $90.77 million. Equities research analysts predict that Organogenesis Holdings Inc. will post -0.07 earnings per share for the current year.

Analyst Ratings Changes

Separately, Morgan Stanley raised their price target on shares of Organogenesis from $4.00 to $6.00 and gave the stock an “equal weight” rating in a report on Wednesday, March 5th.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the business. Strs Ohio purchased a new position in shares of Organogenesis during the first quarter worth $105,000. Driehaus Capital Management LLC purchased a new position in shares of Organogenesis during the first quarter worth $7,756,000. Trexquant Investment LP acquired a new stake in Organogenesis during the first quarter valued at $516,000. OMERS ADMINISTRATION Corp acquired a new stake in Organogenesis during the first quarter valued at $77,000. Finally, Ieq Capital LLC acquired a new stake in Organogenesis during the first quarter valued at $79,000. Hedge funds and other institutional investors own 49.57% of the company’s stock.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.